Clinical Trial: MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: INTERVENTIONAL

Official Title: A Multi-center, Open Label, Phase 1b/2 Study to Study the Efficacy and Safety of MIL62 Plus Lenalidomide in Subjects With Relapsed/Refractory Follicular Lymphoma or Marginal Zone Lymphoma

Brief Summary: This phase 1b/2 trial studies the safety and best dose of lenalidomide when given together with MIL62 and how well this combination works in treating patients with Relapsed/Refractory low-grade Follicular Lymphoma(FL) and Marginal Zone Lymphoma(MZL).
Giving MIL62 plus lenalidomide may work better in indolent Non-Hodgkin Lymphoma(NHL).

Detailed Summary: The Aim of this phase 1b/2 trial (MIL62 Plus Lenalidomide) is to find the safety and best dose of lenalidomide when given together with MIL62 and how well this combination works in treating patients with Relapsed/Refractory low-grade Follicular Lymphoma(FL) and Marginal Zone Lymphoma(MZL).
Giving MIL62 plus lenalidomide may work better in indolent Non-Hodgkin Lymphoma(NHL).
Sponsor: Beijing Mabworks Biotech Co., Ltd.

Current Primary Outcome: Percentage of Participants With an Objective Response of Complete Response

Original Primary Outcome: Percentage of Participants With an Objective Response of Complete Response

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Beijing Mabworks Biotech Co., Ltd.

Dates:
Date Received: September 27, 2019
Date Started: November 28, 2019
Date Completion: May 01, 2025
Last Updated: October 19, 2023
Last Verified: June 01, 2023